ici 204,219 has been researched along with Asthma, Bronchial in 181 studies
zafirlukast: a leukotriene D4 receptor antagonist
| Excerpt | Relevance | Reference |
|---|---|---|
| "The bronchoconstriction caused by inhaled neurokinin A (NKA) in patients with asthma is indirect." | 9.13 | The effect of the leukotriene receptor antagonist zafirlukast on neurokinin A-induced bronchoconstriction in patients with asthma--A comparison with leukotriene D4 induced broncoconstriction. ( Joos, G; Pauwels, R; Schelfhout, V; Van De Velde, V, 2008) |
| "Twenty-four patients with mild-to-moderate asthma were studied using a randomized crossover design with the following three treatment blocks: (1) beclomethasone, 100 microg/d, alone for the first 2 weeks followed by 400 microg/d alone for the next 2 weeks; (2) beclomethasone, 100 microg/d, followed by 400 microg/d, with the addition of zafirlukast, 20 mg bid; (3) beclomethasone, 100 microg/d, followed by 400 microg/d, with the addition of theophylline, 200 to 300 mg bid." | 9.10 | Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. ( Dempsey, OJ; Fowler, SJ; Kennedy, G; Lipworth, BJ; Wilson, A, 2002) |
| "To compare the efficacy and safety of fluticasone propionate and zafirlukast in patients with relatively stable persistent asthma who were previously treated with inhaled corticosteroids and short-acting beta(2)-agonists." | 9.10 | Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma. ( Brabson, JH; Clifford, D; Edwards, LD; Kerwin, E; Pepsin, PJ; Raphael, G; Rickard, K; Srebro, S, 2002) |
| "In the United Kingdom, about 40% of patients with asthma are homozygous for the glycine-16 beta(2)-adrenoceptor polymorphism, which predisposes them to agonist-induced down-regulation and desensitization of the beta(2)-adrenoceptor." | 9.09 | Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype. ( Aziz, I; Dempsey, OJ; Lipworth, BJ; Wilson, AM, 2000) |
| " Two hundred ninety-four patients > or =12 years old with asthma previously uncontrolled with beta-2-agonists alone were randomly assigned to treatment with low-dose inhaled fluticasone (88 microg twice daily) or oral zafirlukast (20 mg twice daily)." | 9.09 | A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma. ( Bleecker, ER; Kalberg, C; Nathan, RA, 2001) |
| "Inhaled fluticasone propionate is more effective than zafirlukast in controlling asthma symptoms, improving pulmonary function, and improving quality of life for patients who are symptomatic with the use of short-acting b2-agonists alone." | 9.09 | Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. ( Bowers, BW; Busse, W; Edwards, L; Johnson, M; Rickard, K; Rogenes, PR; Srebro, S; Storms, W; Wolfe, J, 2001) |
| "Our purpose was to compare the efficacy of a low dose of inhaled fluticasone propionate (FP) with that of oral zafirlukast in the treatment of persistent asthma previously treated with short-acting beta(2)-agonists alone." | 9.09 | Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. ( Bleecker, ER; Edwards, L; Johnson, M; Kalberg, C; Rickard, KA; Weinstein, SF; Welch, MJ, 2000) |
| "To compare the relative value of an inhaled corticosteroid, fluticasone propionate 88 microg twice daily, versus an oral leukotriene receptor antagonist, zafirlukast 20 mg twice daily, in patients with persistent asthma currently receiving short acting beta2-agonists alone." | 9.09 | Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma. ( Edwards, L; Kalberg, C; Menendez, R; Rickard, K; Stanford, RH, 2001) |
| "Inhalation of sulfur dioxide (SO2) causes bronchoconstriction in most people with asthma." | 9.08 | The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma. ( Boushey, HA; Lavins, BJ; Lazarus, SC; Minkwitz, MC; Watts, MJ; Wong, HH, 1997) |
| "The efficacy of 6 wk of therapy with oral ICI 204,219, a selective leukotriene D4 (LTD4) receptor antagonist, was evaluated in subjects with moderate asthma during a multicenter, double-blind, randomized, placebo-controlled, dose-ranging study." | 9.07 | Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. ( Glass, M; Smith, LJ; Spector, SL, 1994) |
| "Three inhalation formulations of ICI 204,219 were compared for antagonism of antigen-induced bronchoconstriction in 16 subjects with asthma who demonstrated reproducible hypersensitivity to allergen during screening challenges." | 9.07 | Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. ( Glass, M; Minkwitz, MC; Nathan, RA, 1994) |
| "Randomized clinical trials have demonstrated that fluticasone propionate (FP) has better objective as well as subjective clinical outcomes than zafirlukast (ZA) in the treatment of asthma." | 7.71 | One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. ( Meyer, JW; Stanford, RH; Stempel, DA; Yancey, SW, 2001) |
| "Aspirin intolerance is characterized by polypous rhinosinusitis, bronchial asthma and adverse reactions to aspirin." | 7.71 | [Zafirlukast in treatment of nasal polyps in patients with aspirin intolerant bronchial asthma--preliminary report]. ( Modrzyński, M; Rapiejko, P; Zawisza, E, 2002) |
| "To compare asthma-related health care expenditures among patients newly prescribed fluticasone propionate 44 or 110 microg, montelukast 5 or 10 mg, or zafirlukast 20 mg." | 7.71 | Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population. ( Davis, EA; Pathak, DS; Stanford, RH, 2002) |
| " No significant shift in the dose-response curve of the quantitative skin test occurred in any subject." | 6.67 | Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. ( Barden, JM; Easley, CB; Findlay, SR; Glass, M, 1992) |
| "ICI 204,219 was tolerated well by all subjects." | 6.67 | Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. ( Glass, M; Minkwitz, MC; Smith, LJ, 1993) |
| "Pulmonary function, asthma symptoms, supplemental albuterol use, asthma quality of life scores, and adverse events." | 6.19 | Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids. ( Kalberg, C; Nathan, RA; Nelson, HS; Rickard, KA; Yancey, SW, 2001) |
| "The bronchoconstriction caused by inhaled neurokinin A (NKA) in patients with asthma is indirect." | 5.13 | The effect of the leukotriene receptor antagonist zafirlukast on neurokinin A-induced bronchoconstriction in patients with asthma--A comparison with leukotriene D4 induced broncoconstriction. ( Joos, G; Pauwels, R; Schelfhout, V; Van De Velde, V, 2008) |
| "To evaluate whether controller medications, particularly leukotriene modifier drugs, taken during oral aspirin challenges can reduce the risk of severe asthmatic responses." | 5.12 | Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. ( Ludington, E; Mehra, P; Simon, RA; Stevenson, DD; White, A, 2006) |
| "To compare the effects of an orally administered corticosteroid (prednisone), an inhaled corticosteroid (flunisolide), a leukotriene-receptor antagonist (zafirlukast), an antiserotonergic drug (cyproheptadine), and a control substance on the asthmatic phenotype in cats with experimentally induced asthma." | 5.11 | Effects of drug treatment on inflammation and hyperreactivity of airways and on immune variables in cats with experimentally induced asthma. ( Berghaus, LJ; Berghaus, RD; Byerly, JR; Decile, KC; Gershwin, LJ; Hyde, DM; Reinero, CR; Schelegle, ES; Walby, WE, 2005) |
| "The objective of this study was to compare the efficacy and safety of the second controller medications (long-acting beta2-agonist, leukotriene receptor antagonist and sustained-release theophylline) used in addition to inhaler corticosteroid treatment in moderate persistent asthma." | 5.10 | Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma. ( Calişir, HC; Ogretensoy, M; Tunçtan, B; Yurdakul, AS, 2002) |
| "Twenty-four patients with mild-to-moderate asthma were studied using a randomized crossover design with the following three treatment blocks: (1) beclomethasone, 100 microg/d, alone for the first 2 weeks followed by 400 microg/d alone for the next 2 weeks; (2) beclomethasone, 100 microg/d, followed by 400 microg/d, with the addition of zafirlukast, 20 mg bid; (3) beclomethasone, 100 microg/d, followed by 400 microg/d, with the addition of theophylline, 200 to 300 mg bid." | 5.10 | Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. ( Dempsey, OJ; Fowler, SJ; Kennedy, G; Lipworth, BJ; Wilson, A, 2002) |
| "To compare the efficacy and safety of fluticasone propionate and zafirlukast in patients with relatively stable persistent asthma who were previously treated with inhaled corticosteroids and short-acting beta(2)-agonists." | 5.10 | Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma. ( Brabson, JH; Clifford, D; Edwards, LD; Kerwin, E; Pepsin, PJ; Raphael, G; Rickard, K; Srebro, S, 2002) |
| "We sought to compare the effect of 4 weeks of treatment with inhaled salmeterol xinafoate versus oral zafirlukast in the treatment of persistent asthma." | 5.09 | Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. ( Busse, W; Kalberg, C; Nelson, H; Rickard, KA; Wolfe, J; Yancey, SW, 1999) |
| "Our purpose was to compare the efficacy of a low dose of inhaled fluticasone propionate (FP) with that of oral zafirlukast in the treatment of persistent asthma previously treated with short-acting beta(2)-agonists alone." | 5.09 | Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. ( Bleecker, ER; Edwards, L; Johnson, M; Kalberg, C; Rickard, KA; Weinstein, SF; Welch, MJ, 2000) |
| "In the United Kingdom, about 40% of patients with asthma are homozygous for the glycine-16 beta(2)-adrenoceptor polymorphism, which predisposes them to agonist-induced down-regulation and desensitization of the beta(2)-adrenoceptor." | 5.09 | Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype. ( Aziz, I; Dempsey, OJ; Lipworth, BJ; Wilson, AM, 2000) |
| "Inhaled fluticasone propionate is more effective than zafirlukast in controlling asthma symptoms, improving pulmonary function, and improving quality of life for patients who are symptomatic with the use of short-acting b2-agonists alone." | 5.09 | Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. ( Bowers, BW; Busse, W; Edwards, L; Johnson, M; Rickard, K; Rogenes, PR; Srebro, S; Storms, W; Wolfe, J, 2001) |
| " Two hundred ninety-four patients > or =12 years old with asthma previously uncontrolled with beta-2-agonists alone were randomly assigned to treatment with low-dose inhaled fluticasone (88 microg twice daily) or oral zafirlukast (20 mg twice daily)." | 5.09 | A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma. ( Bleecker, ER; Kalberg, C; Nathan, RA, 2001) |
| "To compare the relative value of an inhaled corticosteroid, fluticasone propionate 88 microg twice daily, versus an oral leukotriene receptor antagonist, zafirlukast 20 mg twice daily, in patients with persistent asthma currently receiving short acting beta2-agonists alone." | 5.09 | Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma. ( Edwards, L; Kalberg, C; Menendez, R; Rickard, K; Stanford, RH, 2001) |
| "Patients with mild-to-moderate asthma (12 to 76 years old) who were treated with albuterol alone were randomized (nZ = 879; nP = 605) and included in subset analyses." | 5.09 | An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses. ( Bonuccelli, CM; Howland, WC; Minkwitz, MC; Nathan, RA; Simonson, SG; Tashkin, DP, 1999) |
| "To evaluate the effectiveness of zafirlukast (20 mg twice daily) and cromolyn sodium (1600 microg four times daily) compared with placebo as first-line therapy for mild asthma using a retrospective analysis, which stratified patients by PEF variability (<10% or > or =10%)." | 5.09 | Two first-line therapies in the treatment of mild asthma: use of peak flow variability as a predictor of effectiveness. ( Bonuccelli, CM; Minkwitz, MC; Nathan, RA, 1999) |
| "Previous studies demonstrated that leukotriene receptor antagonists (LTRAs) are effective in reducing asthma symptoms and the airway response to inhaled leukotriene D4 (LTD4) in asthmatic patients receiving inhaled beta2-agonists alone." | 5.08 | A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy. ( Hanby, LA; Lavins, BJ; Simonson, SG; Smith, LJ, 1998) |
| "Inhalation of sulfur dioxide (SO2) causes bronchoconstriction in most people with asthma." | 5.08 | The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma. ( Boushey, HA; Lavins, BJ; Lazarus, SC; Minkwitz, MC; Watts, MJ; Wong, HH, 1997) |
| "The efficacy of 6 wk of therapy with oral ICI 204,219, a selective leukotriene D4 (LTD4) receptor antagonist, was evaluated in subjects with moderate asthma during a multicenter, double-blind, randomized, placebo-controlled, dose-ranging study." | 5.07 | Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. ( Glass, M; Smith, LJ; Spector, SL, 1994) |
| "In a double-blind study ten asthmatic patients with impaired lung function received the cysteinyl-leukotriene receptor antagonist ICI 204,219 (40 mg by mouth) and placebo in random order on 2 days at least 1 week apart." | 5.07 | Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. ( Barnes, NC; Hui, KP, 1991) |
| "Three inhalation formulations of ICI 204,219 were compared for antagonism of antigen-induced bronchoconstriction in 16 subjects with asthma who demonstrated reproducible hypersensitivity to allergen during screening challenges." | 5.07 | Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. ( Glass, M; Minkwitz, MC; Nathan, RA, 1994) |
| " Recognition of the involvement of cysLTs in the immunopathogenesis of various types of acute and chronic inflammatory disorders, especially bronchial asthma, prompted the development of selective cysLT receptor-1 (cysLTR1) antagonists, specifically montelukast, pranlukast, and zafirlukast." | 4.90 | Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. ( Anderson, R; Feldman, C; Gravett, CM; Steel, HC; Theron, AJ; Tintinger, GR, 2014) |
| "Montelukast (Singulair-MSD) and zafirlukast (Accolate-AstraZeneca) are oral leukotriene receptor antagonists, licensed for the treatment of patients with asthma." | 4.82 | Leukotriene receptor antagonists--an update. ( , 2005) |
| "To compare the efficacy of fluticasone propionate (FP) and zafirlukast (Z) in younger (12 to 49 years of age) versus older (50 years and older) patients with asthma." | 4.81 | Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age. ( Creticos, P; Dorinsky, P; Edwards, LD; Knobil, K; Rickard, KA, 2002) |
| "The three leukotriene (LT) modifiers approved for use in the United States, zileuton, zafirlukast, and montelukast, are the first new class of therapeutic agents to be introduced in 20 years for the treatment of asthma." | 4.80 | New treatments for asthma: the role of leukotriene modifier agents. ( Valacer, DJ, 1999) |
| "Randomized clinical trials have demonstrated that fluticasone propionate (FP) has better objective as well as subjective clinical outcomes than zafirlukast (ZA) in the treatment of asthma." | 3.71 | One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. ( Meyer, JW; Stanford, RH; Stempel, DA; Yancey, SW, 2001) |
| "This article presents information on the safety of zafirlukast, montelukast, and zileuton, three antileukotrienes (anti-LTs) approved in the United States for the prophylaxis and treatment of asthma." | 3.71 | Safety of antileukotriene agents in asthma management. ( Spector, SL, 2001) |
| "To compare asthma-related health care expenditures among patients newly prescribed fluticasone propionate 44 or 110 microg, montelukast 5 or 10 mg, or zafirlukast 20 mg." | 3.71 | Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population. ( Davis, EA; Pathak, DS; Stanford, RH, 2002) |
| "Aspirin intolerance is characterized by polypous rhinosinusitis, bronchial asthma and adverse reactions to aspirin." | 3.71 | [Zafirlukast in treatment of nasal polyps in patients with aspirin intolerant bronchial asthma--preliminary report]. ( Modrzyński, M; Rapiejko, P; Zawisza, E, 2002) |
| "Zafirlukast, montelukast and pranlukast are all cysteinyl leukotriene receptor antagonists that have recently been approved for the treatment of asthma." | 3.70 | Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal? ( Drazen, JM; Pauwels, R; Wechsler, ME, 1999) |
| "Use of LTRAs in pregnancy was not associated with a specific pattern of major structural anomalies in offspring or a large risk of other adverse perinatal outcomes." | 2.73 | Safety of leukotriene receptor antagonists in pregnancy. ( Bakhireva, LN; Chambers, CD; Johnson, D; Jones, KL; Klonoff-Cohen, HS; Schatz, M; Slymen, DJ, 2007) |
| "This study showed that zafirlukast, as used in general practice in England, is a generally well tolerated drug with few associated adverse events." | 2.73 | Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England. ( Shakir, SA; Twaites, BR; Wilton, LV, 2007) |
| "In both asthmatic and COPD patients, the overall effect of salmeterol and zafirlukast on the forced expiratory volume in 1 s (FEV1) was considered extremely significant (p < 0." | 2.70 | Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease. ( Allegra, L; Boveri, B; Cazzola, M; Centanni, S; Di Marco, F; Matera, MG; Santus, P, 2001) |
| "Single doses of zafirlukast attenuate exercise-induced bronchoconstriction (EIB), but previous studies have not measured zafirlukast's effects after regular dosing or its duration of effect beyond 4 hours." | 2.69 | The effect of zafirlukast on repetitive exercise-induced bronchoconstriction: the possible role of leukotrienes in exercise-induced refractoriness. ( Compagnon, A; Dessanges, JF; Dinh-Xuan, AT; Matran, R; Naya, I; Préfaut, C; Taytard, A, 1999) |
| "Long-term treatment with zafirlukast was safe and well tolerated in asthmatic patients." | 2.69 | Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial. ( Grossman, J; Smith, LJ; Thyrum, PT; Wilson, AM, 1999) |
| "This study was undertaken to examine the dose-response relationship of zafirlukast (5 to 40 mg BID) and to assess the efficacy and tolerability of the 10-mg BID dose in school-aged children with mild to moderate asthma." | 2.69 | Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. ( Bonuccelli, CM; Dowling, PJ; Lampl, KL; Miller, CJ; Pearlman, DS, 2000) |
| "ICI 204,219 is a potent and specific leukotriene D4 receptor antagonist that blocks both the early and late responses to allergen challenge in humans when given orally at a dose of 40 mg." | 2.67 | Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. ( Dollery, CT; O'Connell, F; O'Connor, B; O'Shaughnessy, KM; Taylor, IK; Thomson, H, 1993) |
| "ICI 204,219 was tolerated well by all subjects." | 2.67 | Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. ( Glass, M; Minkwitz, MC; Smith, LJ, 1993) |
| " The allergen dose-response relations were highly reproducible, producing PD20 values at the control session and after placebo treatment which varied by no more than 0." | 2.67 | The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. ( Björck, T; Dahlén, B; Dahlén, SE; Zetterström, O, 1994) |
| " No significant shift in the dose-response curve of the quantitative skin test occurred in any subject." | 2.67 | Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. ( Barden, JM; Easley, CB; Findlay, SR; Glass, M, 1992) |
| "The use of leukotriene inhibitors in treating atopic dermatitis, aspirin-intolerant asthma, and chronic idiopathic urticaria appears promising but has not been studied thoroughly." | 2.44 | Leukotriene inhibitors in the treatment of allergy and asthma. ( Dickerson, KS; Luttermoser, GK; Scow, DT, 2007) |
| " This dosage is also as effective when added to low-dosage inhaled corticosteroid therapy as doubling of corticosteroid dosages." | 2.41 | Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma. ( Dunn, CJ; Goa, KL, 2001) |
| " The absolute bioavailability of zafirlukast is unknown." | 2.41 | Pharmacokinetic profile of zafirlukast. ( Dekhuijzen, PN; Koopmans, PP, 2002) |
| "Today, bronchial asthma is considered as a chronic inflammatory disease of the airway." | 2.41 | [Zafirlukast (Accolate): a review of its pharmacological and clinical profile]. ( Murata, Y; Sugimoto, O, 2002) |
| " Initial data have demonstrated an improvement in pulmonary function and symptom control and a reduction in the use of short-acting inhaled beta 2-adrenoceptor agonist therapy in patients with mild to moderate asthma treated with oral zafirlukast at the recommended dosage of 20 mg twice daily." | 2.40 | Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma. ( Adkins, JC; Brogden, RN, 1998) |
| " The choice of drug and dosage must be individualized to the patient." | 2.40 | Anti-inflammatory drugs for controlling asthma. ( O'Connell, EJ; Volcheck, GW, 1998) |
| " Since the leukotrienes play an important role in the underlying inflammatory processes of asthma, zafirlukast represents a new antiinflammatory option available in an oral dosage form." | 2.40 | Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma. ( Kelloway, JS, 1997) |
| " This new product has been well received due to convenient dosing and relatively few side effects." | 1.30 | Churg-Strauss syndrome associated with zafirlukast. ( Allen, JN; Knoell, DL; Lucas, J, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 80 (44.20) | 18.2507 |
| 2000's | 98 (54.14) | 29.6817 |
| 2010's | 2 (1.10) | 24.3611 |
| 2020's | 1 (0.55) | 2.80 |
| Authors | Studies |
|---|---|
| Itadani, S | 1 |
| Yashiro, K | 1 |
| Aratani, Y | 1 |
| Sekiguchi, T | 1 |
| Kinoshita, A | 1 |
| Moriguchi, H | 1 |
| Ohta, N | 1 |
| Takahashi, S | 1 |
| Ishida, A | 1 |
| Tajima, Y | 1 |
| Hisaichi, K | 1 |
| Ima, M | 1 |
| Ueda, J | 1 |
| Egashira, H | 1 |
| Sekioka, T | 1 |
| Kadode, M | 1 |
| Yonetomi, Y | 1 |
| Nakao, T | 1 |
| Inoue, A | 1 |
| Nomura, H | 1 |
| Kitamine, T | 1 |
| Fujita, M | 1 |
| Nabe, T | 1 |
| Yamaura, Y | 1 |
| Matsumura, N | 1 |
| Imagawa, A | 1 |
| Nakayama, Y | 1 |
| Takeuchi, J | 1 |
| Ohmoto, K | 1 |
| Al-Azzam, N | 1 |
| Elsalem, L | 1 |
| Theron, AJ | 1 |
| Steel, HC | 1 |
| Tintinger, GR | 1 |
| Gravett, CM | 1 |
| Anderson, R | 1 |
| Feldman, C | 1 |
| Yurdakul, AS | 1 |
| Calişir, HC | 1 |
| Tunçtan, B | 1 |
| Ogretensoy, M | 1 |
| Dempsey, OJ | 3 |
| Fowler, SJ | 2 |
| Wilson, A | 1 |
| Kennedy, G | 1 |
| Lipworth, BJ | 5 |
| Ovchinnikov, IuM | 1 |
| Ovcharenko, SI | 1 |
| Ovchinnikov, AIu | 1 |
| Chichkova, NV | 1 |
| Gumeniuk, VA | 1 |
| Kulus, M | 1 |
| Xiang, XD | 1 |
| Zhou, R | 1 |
| Chen, Y | 2 |
| Valacer, DJ | 1 |
| Piatti, G | 1 |
| Ceriotti, L | 1 |
| Cavallaro, G | 1 |
| Ambrosetti, U | 1 |
| Mantovani, M | 1 |
| Pistone, A | 1 |
| Centanni, S | 3 |
| Tonelli, M | 1 |
| Zingoni, M | 1 |
| Bacci, E | 1 |
| Dente, FL | 2 |
| Di Franco, A | 1 |
| Giannini, D | 1 |
| Taccola, M | 1 |
| Vagaggini, B | 1 |
| Paggiaro, PL | 2 |
| Davern, TJ | 1 |
| Bass, NM | 1 |
| Cakir, B | 1 |
| Cykert, S | 1 |
| Keogh, KA | 1 |
| Specks, U | 1 |
| Kumagai, T | 1 |
| Hori, Y | 1 |
| Kishida, Y | 1 |
| Yakumaru, K | 1 |
| Takahashi, T | 1 |
| Itou, T | 1 |
| Huang, CJ | 1 |
| Wang, CH | 1 |
| Liu, WT | 1 |
| Yang, MC | 1 |
| Lin, HC | 1 |
| Yu, CT | 1 |
| Shiao, CJ | 1 |
| Tan, CC | 1 |
| Yang, CK | 1 |
| Kuo, HP | 1 |
| Perng, DW | 1 |
| Huang, HY | 1 |
| Lee, YC | 1 |
| Perng, RP | 1 |
| Wooltorton, E | 1 |
| Silverman, RA | 1 |
| Nowak, RM | 1 |
| Korenblat, PE | 3 |
| Skobeloff, E | 1 |
| Bonuccelli, CM | 6 |
| Miller, CJ | 3 |
| Simonson, SG | 3 |
| Cakmak, G | 1 |
| Demir, T | 1 |
| Gemicioglu, B | 1 |
| Aydemir, A | 1 |
| Serdaroglu, E | 1 |
| Donma, O | 1 |
| Al-Herz, W | 1 |
| Rosé, C | 1 |
| McGeady, SJ | 1 |
| Lau, BH | 1 |
| Riesen, SK | 1 |
| Truong, KP | 1 |
| Lau, EW | 1 |
| Rohdewald, P | 1 |
| Barreta, RA | 1 |
| Laitinen, A | 1 |
| Lindqvist, A | 1 |
| Halme, M | 1 |
| Altraja, A | 1 |
| Laitinen, LA | 1 |
| Boushey, HA | 3 |
| Sorkness, CA | 1 |
| King, TS | 2 |
| Sullivan, SD | 1 |
| Fahy, JV | 1 |
| Lazarus, SC | 3 |
| Chinchilli, VM | 2 |
| Craig, TJ | 1 |
| Dimango, EA | 1 |
| Deykin, A | 3 |
| Fagan, JK | 1 |
| Fish, JE | 1 |
| Ford, JG | 1 |
| Kraft, M | 1 |
| Lemanske, RF | 1 |
| Leone, FT | 1 |
| Martin, RJ | 1 |
| Mauger, EA | 1 |
| Pesola, GR | 1 |
| Peters, SP | 1 |
| Rollings, NJ | 1 |
| Szefler, SJ | 1 |
| Wechsler, ME | 4 |
| Israel, E | 3 |
| Fabbri, LM | 2 |
| Chowdhury, BA | 1 |
| Ng, J | 1 |
| Savage, R | 1 |
| McQueen, F | 1 |
| Reinero, CR | 1 |
| Decile, KC | 1 |
| Byerly, JR | 1 |
| Berghaus, RD | 1 |
| Walby, WE | 1 |
| Berghaus, LJ | 1 |
| Hyde, DM | 1 |
| Schelegle, ES | 1 |
| Gershwin, LJ | 1 |
| Gibbons, FK | 1 |
| Schaub, B | 1 |
| He, HZ | 1 |
| Perkins, DL | 1 |
| Finn, PW | 1 |
| Sveum, RJ | 1 |
| Reyes-Balaguer, J | 1 |
| Hernández de Rojas, D | 1 |
| Antoniu, SA | 1 |
| Stelmach, R | 1 |
| Cukier, A | 1 |
| White, A | 1 |
| Ludington, E | 1 |
| Mehra, P | 1 |
| Stevenson, DD | 1 |
| Simon, RA | 1 |
| Scow, DT | 1 |
| Luttermoser, GK | 1 |
| Dickerson, KS | 1 |
| Bakhireva, LN | 1 |
| Jones, KL | 1 |
| Schatz, M | 1 |
| Klonoff-Cohen, HS | 1 |
| Johnson, D | 1 |
| Slymen, DJ | 1 |
| Chambers, CD | 1 |
| Guilpain, P | 1 |
| Pagnoux, C | 1 |
| Lhote, F | 1 |
| Mouthon, L | 1 |
| Guillevin, L | 1 |
| Steinke, JW | 1 |
| Culp, JA | 1 |
| Twaites, BR | 1 |
| Wilton, LV | 1 |
| Shakir, SA | 1 |
| Schelfhout, V | 1 |
| Van De Velde, V | 1 |
| Pauwels, R | 2 |
| Joos, G | 1 |
| Wang, KL | 1 |
| Carrasco, JL | 1 |
| Reid, DW | 1 |
| Misso, NL | 1 |
| Aggarwal, S | 1 |
| Thompson, PJ | 1 |
| Johns, DP | 1 |
| Walters, EH | 1 |
| Spector, SL | 5 |
| Smith, LJ | 7 |
| Glass, M | 5 |
| Dahlén, B | 3 |
| Zetterström, O | 1 |
| Björck, T | 2 |
| Dahlén, SE | 3 |
| Minkwitz, MC | 8 |
| Nathan, RA | 6 |
| Ford-Hutchinson, AW | 1 |
| O'Shaughnessy, KM | 1 |
| Taylor, IK | 1 |
| O'Connor, B | 1 |
| O'Connell, F | 1 |
| Thomson, H | 1 |
| Dollery, CT | 1 |
| Sakakibara, H | 1 |
| Hirose, K | 1 |
| Okawara, S | 1 |
| Bancalari, L | 1 |
| Bornkessel, B | 1 |
| Suissa, S | 1 |
| Dennis, R | 1 |
| Ernst, P | 1 |
| Sheehy, O | 1 |
| Wood-Dauphinee, S | 1 |
| Grum, CM | 1 |
| Larkin, M | 1 |
| Kupecz, D | 1 |
| Roquet, A | 1 |
| Kumlin, M | 2 |
| Ihre, E | 1 |
| Anstrén, G | 1 |
| Binks, S | 2 |
| Männistö, J | 1 |
| Haahtela, T | 1 |
| Tan, RA | 2 |
| Kelloway, JS | 1 |
| Hendeles, L | 2 |
| Marshik, PL | 1 |
| Wong, HH | 1 |
| Watts, MJ | 1 |
| Lavins, BJ | 3 |
| Estrada, CA | 1 |
| Byrd, J | 1 |
| Honig, PK | 1 |
| Anthracite, R | 1 |
| Jenkins, JK | 1 |
| Adkins, JC | 1 |
| Brogden, RN | 1 |
| Garpestad, E | 1 |
| Flier, SR | 1 |
| Kocher, O | 1 |
| Weiland, DA | 1 |
| Polito, AJ | 1 |
| Klinek, MM | 1 |
| Bigby, TD | 1 |
| Wong, GA | 1 |
| Helmers, RA | 1 |
| Drazen, JM | 6 |
| Wenzel, SE | 2 |
| Dykewicz, MS | 2 |
| Ledford, DK | 1 |
| Horwitz, RJ | 1 |
| McGill, KA | 1 |
| Busse, WW | 1 |
| Calhoun, WJ | 3 |
| Evans, R | 1 |
| Gleich, GJ | 1 |
| Cohn, J | 1 |
| Katz, RS | 1 |
| Papernik, M | 1 |
| Honsinger, RW | 1 |
| Churg, J | 2 |
| Churg, A | 2 |
| Aharony, D | 1 |
| Drazen, J | 1 |
| Knoell, DL | 1 |
| Lucas, J | 1 |
| Allen, JN | 1 |
| Hanby, LA | 2 |
| Panettieri, RA | 1 |
| Tan, EM | 1 |
| Ciocca, V | 1 |
| Luttmann, MA | 1 |
| Leonard, TB | 1 |
| Hay, DW | 1 |
| Volcheck, GW | 1 |
| O'Connell, EJ | 1 |
| Fehrenbach, C | 1 |
| Santais, MC | 1 |
| Callens, E | 1 |
| Djebbar, R | 1 |
| Ruff, F | 1 |
| Bernstein, JA | 1 |
| Bielory, L | 1 |
| Galant, SP | 1 |
| Kemp, JP | 4 |
| Kylstra, JW | 1 |
| Nayak, AS | 1 |
| O'Connor, JP | 1 |
| Schwartz, HJ | 1 |
| Southern, DL | 1 |
| Williams, PV | 1 |
| Lane, SJ | 1 |
| Tashkin, DP | 1 |
| Howland, WC | 1 |
| Warren, MS | 1 |
| Rosenwasser, LJ | 1 |
| Finkel, TH | 1 |
| Hunter, DJ | 1 |
| Paisley, JE | 1 |
| Finkel, RS | 1 |
| Larsen, GL | 1 |
| Grossman, J | 1 |
| Wilson, AM | 3 |
| Thyrum, PT | 1 |
| Dicpinigaitis, PV | 2 |
| Dobkin, JB | 2 |
| Busse, W | 2 |
| Nelson, H | 1 |
| Wolfe, J | 2 |
| Kalberg, C | 5 |
| Yancey, SW | 4 |
| Rickard, KA | 5 |
| Wechsler, M | 1 |
| Green, L | 1 |
| Scherger, JE | 2 |
| Minkwitz, M | 1 |
| Naményi, M | 1 |
| Puha, K | 1 |
| Pánczél, G | 1 |
| Mikó, P | 1 |
| Fäller, K | 1 |
| Dér, K | 1 |
| Ulualp, SO | 1 |
| Sterman, BM | 1 |
| Toohill, RJ | 1 |
| Kroegel, C | 1 |
| Reissig, A | 1 |
| Hengst, U | 1 |
| Petrovic, A | 1 |
| Häfner, D | 1 |
| Grahmann, RP | 1 |
| Anderson, P | 1 |
| Dessanges, JF | 1 |
| Préfaut, C | 1 |
| Taytard, A | 1 |
| Matran, R | 1 |
| Naya, I | 4 |
| Compagnon, A | 1 |
| Dinh-Xuan, AT | 1 |
| Thien, FC | 1 |
| Kupczyk, M | 1 |
| Kuna, P | 1 |
| Westbroek, J | 1 |
| Pasma, HR | 1 |
| Meltzer, EO | 1 |
| Mezzanotte, W | 1 |
| Phipatanakul, W | 1 |
| Eggleston, PA | 1 |
| Conover-Walker, MK | 1 |
| Kesavanathan, J | 1 |
| Sweitzer, D | 1 |
| Wood, RA | 1 |
| Weinberg, EG | 1 |
| Richter, K | 1 |
| Jörres, RA | 1 |
| Magnussen, H | 1 |
| D'Urzo, AD | 1 |
| Chapman, KR | 1 |
| Stey, C | 1 |
| Barnes, NC | 2 |
| Bleecker, ER | 2 |
| Welch, MJ | 1 |
| Weinstein, SF | 1 |
| Johnson, M | 2 |
| Edwards, L | 3 |
| Weinberger, M | 1 |
| Pearlman, DS | 1 |
| Lampl, KL | 1 |
| Dowling, PJ | 1 |
| Virchow, JC | 1 |
| Prasse, A | 1 |
| Summerton, L | 1 |
| Harris, A | 1 |
| Aziz, I | 1 |
| Sampson, AP | 1 |
| Siddiqui, S | 1 |
| Buchanan, D | 1 |
| Howarth, PH | 1 |
| Holgate, ST | 1 |
| Holloway, JW | 1 |
| Sayers, I | 1 |
| Chung, KF | 1 |
| Stoloff, S | 1 |
| Stempel, DA | 2 |
| Santus, P | 2 |
| Casanova, F | 1 |
| Di Marco, F | 2 |
| Brazzola, G | 1 |
| Canonica, GW | 1 |
| Meyer, JW | 1 |
| Stanford, RH | 3 |
| Bisgaard, H | 1 |
| Dunn, CJ | 1 |
| Goa, KL | 1 |
| Morishita, M | 1 |
| Tsai, JJ | 2 |
| Chan, SC | 2 |
| Ho, CK | 2 |
| Su, YC | 2 |
| Feng, TC | 2 |
| Krawiec, ME | 1 |
| García-Marcos, L | 1 |
| Schuster, A | 1 |
| Dorinsky, PM | 1 |
| Edwards, LD | 3 |
| Storms, W | 1 |
| Srebro, S | 2 |
| Bowers, BW | 1 |
| Rogenes, PR | 1 |
| Rickard, K | 3 |
| Nelson, HS | 1 |
| Menendez, R | 1 |
| Minoguchi, K | 1 |
| Adachi, M | 1 |
| Cates, C | 1 |
| Lanz, MJ | 1 |
| Eisenlohr, C | 1 |
| Llabre, MM | 1 |
| Toledo, Y | 1 |
| Lanz, MA | 1 |
| Cazzola, M | 1 |
| Boveri, B | 1 |
| Matera, MG | 1 |
| Allegra, L | 1 |
| Hayden, ML | 1 |
| Guo, Y | 1 |
| Sun, T | 1 |
| Zhang, H | 1 |
| Segal, R | 1 |
| Pathak, DS | 1 |
| Davis, EA | 1 |
| Dekhuijzen, PN | 1 |
| Koopmans, PP | 1 |
| Aelony, Y | 1 |
| Palmer, LJ | 1 |
| Silverman, ES | 1 |
| Weiss, ST | 1 |
| Murata, Y | 1 |
| Sugimoto, O | 1 |
| Janson, S | 1 |
| Buccellati, C | 1 |
| Fumagalli, F | 1 |
| Viappiani, S | 1 |
| Folco, G | 1 |
| Creticos, P | 1 |
| Knobil, K | 1 |
| Dorinsky, P | 1 |
| Naberan Toña, KX | 1 |
| Martínez González, A | 1 |
| Mendia, JL | 1 |
| Modrzyński, M | 1 |
| Zawisza, E | 1 |
| Rapiejko, P | 1 |
| Reichel, J | 1 |
| Richeldi, L | 1 |
| Rossi, G | 1 |
| Ruggieri, MP | 1 |
| Corbetta, L | 1 |
| Brabson, JH | 1 |
| Clifford, D | 1 |
| Kerwin, E | 1 |
| Raphael, G | 1 |
| Pepsin, PJ | 1 |
| Hall, IP | 1 |
| Wheatley, AP | 1 |
| Findlay, SR | 1 |
| Barden, JM | 1 |
| Easley, CB | 1 |
| Cheng, JB | 1 |
| Hui, KP | 1 |
| Eliasson, E | 1 |
| Johansson, H | 1 |
| Boo, K | 1 |
| Whitney, J | 1 |
| King, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Asthma Clinical Research Network (ACRN)[NCT00000577] | Phase 3 | 0 participants (Actual) | Interventional | 1993-09-30 | Withdrawn (stopped due to Record is an ACRN grant summary & not reflective of an individual trial. All ACTs conducted by ACRN were individually registered on the PRS.) | ||
| Predicting the Bronchoprotective Response to a Leukotriene Modifier by Genetic Polymorphism[NCT00116324] | Phase 3 | 150 participants | Interventional | 2003-04-30 | Completed | ||
| The Utility of feNO in the Differential Diagnosis of Chronic Cough: The Response to Anti-inflammatory Therapy With Prednisolone and Montelukast[NCT02479074] | Phase 4 | 49 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
60 reviews available for ici 204,219 and Asthma, Bronchial
| Article | Year |
|---|---|
Leukotriene D
Topics: Acetates; Airway Remodeling; Animals; Anti-Asthmatic Agents; Asthma; Bronchial Hyperreactivity; Cycl | 2020 |
Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Acetates; Anti-Asthmatic Agents; Arachidonate 5-Lipoxygenase; A | 2014 |
[Leukotriene antagonist drugs].
Topics: Acetates; Anti-Asthmatic Agents; Asthma; Cyclopropanes; Humans; Indoles; Leukotriene Antagonists; Ph | 2002 |
New treatments for asthma: the role of leukotriene modifier agents.
Topics: Acetates; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Asthma, Exercise-I | 1999 |
Leukotriene antagonists.
Topics: Adult; Aged; Anti-Asthmatic Agents; Asthma; Chemical and Drug Induced Liver Injury; Female; Humans; | 2003 |
Childhood asthma. Balancing efficacy and adherence for optimum management.
Topics: Acetates; Adolescent; Adult; Anti-Asthmatic Agents; Asthma; Child; Child, Preschool; Cyclopropanes; | 2005 |
Leukotriene receptor antagonists--an update.
Topics: Acetates; Administration, Inhalation; Adolescent; Adult; Asthma; Child; Child, Preschool; Cyclopropa | 2005 |
Leukotriene inhibitors in the treatment of allergy and asthma.
Topics: Acetates; Anti-Asthmatic Agents; Asthma; Asthma, Exercise-Induced; Cyclopropanes; Dermatitis, Atopic | 2007 |
[Antileukotrienes and Churg-Strauss syndrome].
Topics: Acetates; Adult; Anti-Asthmatic Agents; Antibodies, Antineutrophil Cytoplasmic; Asthma; Chromones; C | 2007 |
Leukotriene synthesis inhibitors versus antagonists: the pros and cons.
Topics: Acetates; Animals; Anti-Asthmatic Agents; Arachidonate 5-Lipoxygenase; Asthma; Chromones; Cyclopropa | 2007 |
Leukotriene antagonists and inhibitors as modulators of IgE-mediated reactions.
Topics: Arachidonate 5-Lipoxygenase; Asthma; Clinical Trials as Topic; Humans; Immunoglobulin E; Indoles; Ph | 1993 |
Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents.
Topics: Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Humans; Hydroxyurea | 1996 |
Management of asthma with zafirlukast. Clinical experience and tolerability profile.
Topics: Anti-Asthmatic Agents; Asthma; Clinical Trials as Topic; Humans; Indoles; Leukotriene Antagonists; L | 1996 |
[Peptidoleukotriene receptor antagonists in asthma therapy].
Topics: Asthma; Chromones; Humans; Indoles; Leukotriene Antagonists; Phenylcarbamates; Propionates; Quinolin | 1996 |
[Clinical pharmacology of leucotriene inhibitors].
Topics: Anti-Asthmatic Agents; Asthma; Humans; Indoles; Leukotriene Antagonists; Phenylcarbamates; Sulfonami | 1996 |
[Leukotriene receptor antagonists].
Topics: Administration, Inhalation; Administration, Oral; Anti-Asthmatic Agents; Asthma; Humans; Indoles; Le | 1996 |
[New drugs in asthma treatment. Leukotriene receptor blockers and leukotriene synthesis inhibitors].
Topics: Airway Obstruction; Anti-Asthmatic Agents; Asthma; Bronchial Hyperreactivity; Humans; Indoles; Leuko | 1997 |
Antileukotriene agents.
Topics: Anti-Asthmatic Agents; Asthma; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leukotrienes; | 1997 |
Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma.
Topics: Animals; Anti-Asthmatic Agents; Asthma; Clinical Trials as Topic; Humans; Indoles; Leukotriene Antag | 1997 |
Zafirlukast for chronic asthma: convenient and generally safe, but is it effective?
Topics: Anti-Asthmatic Agents; Asthma; Chronic Disease; Humans; Indoles; Leukotriene Antagonists; Phenylcarb | 1997 |
Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma.
Topics: Anti-Asthmatic Agents; Asthma; Clinical Trials as Topic; Humans; Indoles; Leukotriene Antagonists; P | 1998 |
New directions in asthma drug therapy.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Chromones; Humans; Hydroxyur | 1998 |
The role of antileukotrienes in asthma management.
Topics: Acetates; Animals; Anti-Asthmatic Agents; Asthma; Chromones; Cyclopropanes; Humans; Hydroxyurea; Ind | 1998 |
New approaches to anti-inflammatory therapy for asthma.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Di | 1998 |
Recent findings in asthma likely to impact patient care.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Gastroesophageal Reflux; Humans; | 1998 |
The role of leukotriene modifiers in the treatment of asthma.
Topics: Animals; Asthma; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leukotrienes; Lipoxygenase I | 1998 |
Pharmacology of leukotriene receptor antagonists.
Topics: Acetates; Animals; Anti-Asthmatic Agents; Asthma; Bronchoconstriction; Cyclopropanes; Dicarboxylic A | 1998 |
Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Humans; Hydroxyurea; Indoles | 1998 |
Summary of clinical trials with zafirlukast.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchoconstriction; Clinica | 1998 |
Anti-inflammatory drugs for controlling asthma.
Topics: Adult; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Child; Cromolyn Sodium; Glucocortico | 1998 |
A risk-benefit assessment of antileukotrienes in asthma.
Topics: Anti-Asthmatic Agents; Aspirin; Asthma; Bronchodilator Agents; Cold Temperature; Drug Interactions; | 1998 |
A new treatment option in asthma management.
Topics: Adult; Anti-Asthmatic Agents; Asthma; Child; Humans; Indoles; Leukotriene Antagonists; Phenylcarbama | 1998 |
[Potential importance of antileukotrienes in the treatment of asthma and other inflammatory diseases: apropos of a new pharmacological class].
Topics: Acetophenones; Adult; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthr | 1998 |
Leukotriene antagonism in asthma and rhinitis.
Topics: Acetates; Asthma; Bronchi; Cyclopropanes; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leu | 1998 |
Leukotriene-receptor antagonists.
Topics: Acetates; Adolescent; Adult; Anti-Asthmatic Agents; Asthma; Child; Cyclopropanes; Drug Administratio | 1999 |
Montelukast and zafirlukast in asthma.
Topics: Acetates; Adult; Anti-Asthmatic Agents; Asthma; Asthma, Exercise-Induced; Child; Cyclopropanes; Huma | 1998 |
Newer therapeutic agents for asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator A | 1999 |
[The role of leukotrienes in inflammation and leukotriene inhibitors].
Topics: Acetates; Arachidonate 5-Lipoxygenase; Asthma; Cyclopropanes; Humans; Hydroxyurea; Indoles; Leukotri | 1999 |
Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of "one linked airway disease".
Topics: Asthma; Humans; Indoles; Leukotriene Antagonists; Membrane Proteins; Phenylcarbamates; Receptors, Le | 2000 |
Leukotriene-receptor antagonists. Role in asthma management.
Topics: Acetates; Adrenal Cortex Hormones; Anti-Asthmatic Agents; Asthma; Bronchial Spasm; Chronic Disease; | 2000 |
[Leukotriene antagonists--do they have a value?].
Topics: Acetates; Anti-Asthmatic Agents; Asthma; Cyclopropanes; Humans; Indoles; Leukotriene Antagonists; Ph | 2000 |
Leukotriene receptor antagonist therapy.
Topics: Acetates; Anti-Asthmatic Agents; Asthma; Asthma, Exercise-Induced; Chronic Disease; Cyclopropanes; H | 2000 |
Leukotriene modifiers in pediatric asthma management.
Topics: Acetates; Adrenal Cortex Hormones; Anti-Asthmatic Agents; Asthma; Child; Cyclopropanes; Humans; Hydr | 2001 |
Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Child | 2001 |
Leukotriene inhibitors and non-steroidal therapies in the treatment of asthma.
Topics: Acetates; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Asthma; Bronchocon | 2001 |
Antileukotrienes in asthma: present situation.
Topics: Acetates; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Chromones; Clinical Trials as Topic; | 2001 |
Comparative efficacy of inhaled corticosteroids and antileukotriene drugs in asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Androstadienes; Anti-Asthmatic Agents; Asthma; | 2001 |
Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Anti-A | 2001 |
[Leukotriene modifiers].
Topics: Acetates; Asthma; Chromones; Cyclopropanes; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; L | 2001 |
Chronic asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Beclomethasone; Chronic Dis | 2001 |
Leukotriene modifiers. Expanded role may be on horizon.
Topics: Acetates; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Cyclopropanes; Drug Interactions; | 2000 |
Pharmacokinetic profile of zafirlukast.
Topics: Anti-Asthmatic Agents; Asthma; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Humans; Indole | 2002 |
Pharmacogenetics of asthma.
Topics: Adrenergic beta-Agonists; Anti-Asthmatic Agents; Arachidonate 5-Lipoxygenase; Asthma; Gene Frequency | 2002 |
[Zafirlukast (Accolate): a review of its pharmacological and clinical profile].
Topics: Animals; Anti-Asthmatic Agents; Asthma; Binding, Competitive; Bronchoconstriction; Clinical Trials a | 2002 |
Where do leukotriene modifiers fit in asthma management?
Topics: Acetates; Asthma; Child; Churg-Strauss Syndrome; Cyclopropanes; Forced Expiratory Volume; Humans; In | 2002 |
Leukotriene modifiers: novel therapeutic opportunities in asthma.
Topics: Animals; Anti-Asthmatic Agents; Asthma; Drug Evaluation, Preclinical; Humans; Indoles; Leukotriene A | 2002 |
Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Androstadienes; Anti-Asthmatic Agents; Asth | 2002 |
[Reflections on antileukotrienes].
Topics: Acetates; Anti-Asthmatic Agents; Asthma; Cyclopropanes; Humans; Indoles; Leukotriene Antagonists; Ph | 2002 |
Early efficacy data with a newer generation of LTD4 antagonists in antiasthma trials: early promise for a single mediator antagonist.
Topics: Acetophenones; Animals; Asthma; Bronchodilator Agents; Humans; Indoles; Phenylcarbamates; Propionate | 1992 |
Initial results with oral administration of ICI 204,219.
Topics: Administration, Oral; Asthma; Humans; Indoles; Leukotriene Antagonists; Lung; Phenylcarbamates; Skin | 1991 |
61 trials available for ici 204,219 and Asthma, Bronchial
| Article | Year |
|---|---|
Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma.
Topics: Adrenergic beta-Agonists; Adult; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Budesonide; D | 2002 |
Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Anti-Asthmatic Agents; Asthma; Beclomethaso | 2002 |
[Anti-leukotriene therapy of patients with allergic rhinosinusitis and bronchial asthma].
Topics: Adult; Anti-Asthmatic Agents; Asthma; Female; Humans; Indoles; Leukotriene Antagonists; Male; Middle | 2002 |
[Influence of zafirlukast on pulmonary functions and quality of life in patients with asthma].
Topics: Adolescent; Adult; Anti-Asthmatic Agents; Asthma; Female; Humans; Indoles; Lung; Male; Middle Aged; | 2001 |
Effects of zafirlukast on bronchial asthma and allergic rhinitis.
Topics: Adolescent; Adult; Airway Resistance; Anti-Asthmatic Agents; Asthma; Cilia; Female; Humans; Indoles; | 2003 |
Short-term effect of the addition of leukotriene receptor antagonists to the current therapy in severe asthmatics.
Topics: Acetates; Anti-Asthmatic Agents; Asthma; Cyclopropanes; Female; Humans; Indoles; Leukotriene Antagon | 2003 |
Zafirlukast improves pulmonary function in patients with moderate persistent asthma receiving regular inhaled steroids: a prospective randomized control study.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Aged; Asthma; Double-Blind Method; Femal | 2003 |
Leukotriene modifier vs inhaled corticosteroid in mild-to-moderate asthma: clinical and anti-inflammatory effects.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Asthma; Budesonide; F | 2004 |
Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Asthmatic Agents; Asthma; Child; Double-Blind Method; E | 2004 |
The effects of add-on zafirlukast treatment to budesonide on bronchial hyperresponsiveness and serum levels of eosinophilic cationic protein and total antioxidant capacity in asthmatic patients.
Topics: Adolescent; Adult; Antioxidants; Asthma; Bronchial Hyperreactivity; Bronchodilator Agents; Budesonid | 2004 |
Pycnogenol as an adjunct in the management of childhood asthma.
Topics: Adolescent; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Antioxidants; Asthma; Bronch | 2004 |
Leukotriene E(4)-induced persistent eosinophilia and airway obstruction are reversed by zafirlukast in patients with asthma.
Topics: Administration, Inhalation; Adult; Airway Obstruction; Anti-Asthmatic Agents; Asthma; Bronchial Prov | 2005 |
Daily versus as-needed corticosteroids for mild persistent asthma.
Topics: Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adult; Anti-Asthmatic Age | 2005 |
Effects of drug treatment on inflammation and hyperreactivity of airways and on immune variables in cats with experimentally induced asthma.
Topics: Airway Resistance; Animals; Anti-Asthmatic Agents; Asthma; Bronchial Spasm; Bronchoalveolar Lavage F | 2005 |
The combined effects of zafirlukast, prednisone, and inhaled budesonide on IL-13 and IFN-gamma secretion.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Asthma; Budesonide; Drug Therapy, Combination; | 2005 |
Effect of leukotriene modifier drugs on the safety of oral aspirin challenges.
Topics: Acetates; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Asthmatic Agents; Aspirin; Asthma; | 2006 |
Safety of leukotriene receptor antagonists in pregnancy.
Topics: Acetates; Adult; Anti-Asthmatic Agents; Asthma; Cyclopropanes; Female; Fetus; Humans; Indoles; Infan | 2007 |
Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Asthma; Child; Child, Preschool; Cohort | 2007 |
The effect of the leukotriene receptor antagonist zafirlukast on neurokinin A-induced bronchoconstriction in patients with asthma--A comparison with leukotriene D4 induced broncoconstriction.
Topics: Adult; Arachidonate 5-Lipoxygenase; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Cross- | 2008 |
Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Analysis of Variance; Asthma; Chi-Square Distribution | 1994 |
The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics.
Topics: Adult; Allergens; Asthma; Bronchial Provocation Tests; Double-Blind Method; Forced Expiratory Volume | 1994 |
Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219.
Topics: Adolescent; Adult; Analysis of Variance; Asthma; Bronchial Provocation Tests; Bronchoconstriction; D | 1993 |
Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma.
Topics: Administration, Inhalation; Adult; Allergens; Antigens; Asthma; Bronchial Provocation Tests; Broncho | 1994 |
Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction.
Topics: Administration, Inhalation; Adult; Allergens; Analysis of Variance; Asthma; Bronchoconstriction; Fem | 1993 |
Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.
Topics: Absenteeism; Adult; Anti-Asthmatic Agents; Asthma; Female; Follow-Up Studies; Health Services; Human | 1997 |
Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics.
Topics: Adolescent; Adult; Airway Obstruction; Allergens; Anti-Asthmatic Agents; Asthma; Drug Therapy, Combi | 1997 |
The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma.
Topics: Adult; Airway Resistance; Anti-Asthmatic Agents; Asthma; Bronchoconstriction; Cross-Over Studies; Do | 1997 |
Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge.
Topics: Adolescent; Adult; Antigens; Asthma; Bronchoalveolar Lavage Fluid; Cell Count; Cross-Over Studies; D | 1998 |
A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Anti-Asthmatic Agents; Asthma; Bronchoco | 1998 |
Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction.
Topics: Adolescent; Adult; Aged; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Humans; | 1998 |
An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Anti-Asthmatic Agents; | 1999 |
Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma.
Topics: Adult; Anti-Asthmatic Agents; Asthma; Double-Blind Method; Female; Forced Expiratory Volume; Humans; | 1999 |
Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Asthma; Child; Female; Humans; Indoles; Leukotriene | 1999 |
Effect of zafirlukast on cough reflex sensitivity in asthmatics.
Topics: Administration, Oral; Adult; Aged; Anti-Asthmatic Agents; Asthma; Capsaicin; Cough; Cross-Over Studi | 1999 |
Two first-line therapies in the treatment of mild asthma: use of peak flow variability as a predictor of effectiveness.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Asthma; Child; Circadian Rhythm; Cromolyn Sodium; Do | 1999 |
Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Adult; Aged; | 1999 |
Zafirlukast in clinical practice: results of the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) in patients with asthma.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Asthma; Child; Family Practice; Female; Humans; Indo | 1999 |
[Zafirlukast therapy of patients with mild-to-moderate bronchial asthma].
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Asthma; Cysteine; Female; Humans; Indoles; Leukotrie | 1999 |
The effect of zafirlukast on repetitive exercise-induced bronchoconstriction: the possible role of leukotrienes in exercise-induced refractoriness.
Topics: Adolescent; Adult; Area Under Curve; Asthma; Bronchoconstriction; Exercise; Female; Forced Expirator | 1999 |
Effects of 2 weeks of treatment with fluticasone propionate 100 mcg b.d. by comparison with zafirlukast 20 mg b.d. on bronchial hyper-responsiveness in patients with mild to moderate asthma.
Topics: Adolescent; Adult; Aged; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchial Hyperreactivity; C | 2000 |
Effect of age on response to zafirlukast in patients with asthma in the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT).
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Age Factors; Aged; Asthma; Female; Forced Expiratory Vo | 2000 |
A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge.
Topics: Adult; Allergens; Animals; Asthma; Cats; Double-Blind Method; Female; Forced Expiratory Volume; Glyc | 2000 |
Treatment preferences of adolescent patients with asthma.
Topics: Administration, Oral; Adolescent; Anti-Asthmatic Agents; Asthma; Beclomethasone; Child; Cross-Over S | 2000 |
Efficacy and duration of action of the antileukotriene zafirlukast on cold air-induced bronchoconstriction.
Topics: Administration, Inhalation; Adult; Air; Analysis of Variance; Asthma; Bronchial Provocation Tests; B | 2000 |
Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Asthma; Double-Blind Method; Female; Forced Expirato | 2000 |
Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Androstadienes; Anti-Asthmatic Agents | 2000 |
Effectiveness and tolerability of zafirlukast for the treatment of asthma in children.
Topics: Adolescent; Anti-Asthmatic Agents; Asthma; Child; Dose-Response Relationship, Drug; Double-Blind Met | 2000 |
Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Ag | 2000 |
Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Anti-Asthmatic Agents; Asthma; Be | 2000 |
Compliance with an oral asthma medication: a pilot study using an electronic monitoring device.
Topics: Administration, Oral; Adolescent; Adult; Anti-Asthmatic Agents; Asthma; Data Interpretation, Statist | 2000 |
Efficacy of zafirlukast in the treatment of patients with bronchial asthma.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Age Factors; Aged; A | 2001 |
Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Androstadienes; Anti-Asth | 2001 |
A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Androstadienes; Anti-Asthmatic Agents; Anti-Inf | 2001 |
Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Anti-A | 2001 |
Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma.
Topics: Adult; Androstadienes; Anti-Asthmatic Agents; Asthma; Cost-Benefit Analysis; Female; Fluticasone; Ho | 2001 |
The effect of low-dose inhaled fluticasone propionate on exhaled nitric oxide in asthmatic patients and comparison with oral zafirlukast.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Androstadienes; Anti-Asthmatic | 2001 |
Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Cross-Over | 2001 |
Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma.
Topics: Adult; Anti-Asthmatic Agents; Asthma; Bronchial Provocation Tests; Capsaicin; Cough; Cross-Over Stud | 2002 |
Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma.
Topics: Adrenal Cortex Hormones; Adult; Androstadienes; Anti-Asthmatic Agents; Asthma; Double-Blind Method; | 2002 |
Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma.
Topics: Administration, Oral; Adolescent; Adult; Antigens; Asthma; Bronchial Provocation Tests; Bronchoconst | 1992 |
Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist.
Topics: Administration, Inhalation; Adult; Airway Resistance; Albuterol; Asthma; Bronchoconstriction; Double | 1991 |
61 other studies available for ici 204,219 and Asthma, Bronchial
| Article | Year |
|---|---|
Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma.
Topics: Animals; Asthma; Biological Availability; Butyrates; Dogs; Guinea Pigs; Humans; Indoles; Leukotriene | 2015 |
Asthma associated with worsening leg ulcer: a case of vasculitis in primary care.
Topics: Aged; Anti-Asthmatic Agents; Asthma; Biopsy; Churg-Strauss Syndrome; Diabetes Mellitus, Type 2; Diag | 2003 |
Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists.
Topics: Acetates; Adolescent; Adult; Aged; Antibodies, Antineutrophil Cytoplasmic; Asthma; Biopsy; Central N | 2003 |
Acute renal failure and nephrotic syndrome associated with zafirlukast therapy.
Topics: Acute Kidney Injury; Anti-Asthmatic Agents; Asthma; Biopsy, Needle; Follow-Up Studies; Humans; Immun | 2003 |
Asthma drug zafirlukast (Accolate): serious hepatic events.
Topics: Anti-Asthmatic Agents; Asthma; Chemical and Drug Induced Liver Injury; Drug Interactions; Humans; In | 2004 |
Cutaneous vasculitis associated with zafirlukast use in asthma.
Topics: Asthma; Child; Humans; Indoles; Leukotriene Antagonists; Male; Phenylcarbamates; Sulfonamides; Tosyl | 2004 |
Does mild persistent asthma require regular treatment?
Topics: Administration, Inhalation; Administration, Oral; Anti-Asthmatic Agents; Asthma; Budesonide; Drug Ad | 2005 |
Treatment of mild asthma.
Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Asthma; Budesonide; Drug Administration Schedule; Fo | 2005 |
Daily inhaled corticosteroid treatment should not be prescribed for mild persistent asthma. Con.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Asthma; Bronchodilator Agents; Budesonide; Clin | 2005 |
Churg-Strauss vasculitis syndrome and leukotriene receptor antagonists.
Topics: Adult; Anti-Asthmatic Agents; Asthma; Churg-Strauss Syndrome; Female; Humans; Indoles; Leukotriene A | 2005 |
Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Asthma; Churg-Strauss Syndrome; Humans; Indoles; Leukotrien | 2006 |
Daily versus intermittent corticosteroids for the treatment of mild persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Asthma; Budesonide; D | 2006 |
Treating allergic rhinitis and asthma: different sides of the same fence.
Topics: Adrenal Cortex Hormones; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, | 2006 |
A class of repeated measures concordance correlation coefficients.
Topics: Absorptiometry, Photon; Adolescent; Adrenal Cortex Hormones; Algorithms; Anti-Asthmatic Agents; Asth | 2007 |
Tolerance and rebound with zafirlukast in patients with persistent asthma.
Topics: Adult; Aged; Asthma; Dinoprostone; Double-Blind Method; Female; Humans; Indoles; Leukotriene Antagon | 2008 |
FDA approves zafirlukast, first of new type of asthma drug.
Topics: Anti-Asthmatic Agents; Asthma; Drug Interactions; Humans; Indoles; Leukotriene Antagonists; Phenylca | 1996 |
Zafirlukast for asthma.
Topics: Anti-Asthmatic Agents; Asthma; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship | 1996 |
Disturbing asthma statistics reflect suboptimal management.
Topics: Adrenergic beta-Agonists; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Budesonide; Human | 1997 |
New asthma drugs target inflammatory cascade.
Topics: Anti-Asthmatic Agents; Asthma; Humans; Indoles; Inflammation; Leukotriene Antagonists; Phenylcarbama | 1997 |
Zafirlukast: a new treatment for asthma.
Topics: Anti-Asthmatic Agents; Asthma; Drug Costs; Humans; Indoles; Leukotrienes; Phenylcarbamates; Sulfonam | 1997 |
Zafirlukast in asthma.
Topics: Anti-Asthmatic Agents; Asthma; Humans; Indoles; Phenylcarbamates; Randomized Controlled Trials as To | 1998 |
Zafirlukast in asthma.
Topics: Anti-Asthmatic Agents; Asthma; Humans; Indoles; Peer Review; Phenylcarbamates; Research Design; Sulf | 1998 |
Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast.
Topics: Adult; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Cardiomyopathies; Churg-Strauss Synd | 1998 |
Zafirlukast and Churg-Strauss syndrome.
Topics: Anti-Asthmatic Agents; Asthma; Churg-Strauss Syndrome; Female; Glucocorticoids; Humans; Indoles; Mid | 1998 |
Zafirlukast and Churg-Strauss syndrome.
Topics: Anti-Asthmatic Agents; Asthma; Churg-Strauss Syndrome; Humans; Indoles; Leukotriene Antagonists; Phe | 1998 |
Zafirlukast and Churg-Strauss syndrome.
Topics: Anti-Asthmatic Agents; Asthma; Churg-Strauss Syndrome; Glucocorticoids; Humans; Indoles; Phenylcarba | 1998 |
Churg-Strauss syndrome associated with zafirlukast.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents; Arthralgia; Asthma; Churg-Strauss Syndrome; Exanthe | 1998 |
Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction In vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists.
Topics: Asthma; Carbachol; Cells, Cultured; Chromones; Dicarboxylic Acids; DNA Replication; Epidermal Growth | 1998 |
Steroids and Churg-Strauss syndrome.
Topics: Anti-Asthmatic Agents; Asthma; Churg-Strauss Syndrome; Humans; Indoles; Leukotriene Antagonists; Phe | 1998 |
Drugs for asthma.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adr | 1999 |
The emerging role of leukotriene antagonists in asthma therapy.
Topics: Acetates; Adrenergic beta-Agonists; Anti-Asthmatic Agents; Asthma; Cyclopropanes; Glucocorticoids; H | 1999 |
Leukotriene modifiers: new drugs, old and new reactions.
Topics: Acetates; Anti-Asthmatic Agents; Asthma; Autoimmune Diseases; Chromones; Churg-Strauss Syndrome; Cyc | 1999 |
Drug-induced lupus in a child after treatment with zafirlukast (Accolate).
Topics: Anti-Asthmatic Agents; Asthma; Child; Female; Humans; Indoles; Leukotriene Antagonists; Lupus Erythe | 1999 |
Churg-Strauss syndrome.
Topics: Anti-Asthmatic Agents; Asthma; Churg-Strauss Syndrome; Humans; Indoles; Phenylcarbamates; Sulfonamid | 1999 |
On studying effectiveness.
Topics: Anti-Asthmatic Agents; Asthma; Clinical Trials as Topic; Cohort Studies; Family Practice; Humans; In | 1999 |
Zafirlukast and Churg-Strauss syndrome.
Topics: Anti-Asthmatic Agents; Asthma; Churg-Strauss Syndrome; Humans; Indoles; Phenylcarbamates; Sulfonamid | 1999 |
Antileukotriene therapy for the relief of sinus symptoms in aspirin triad disease.
Topics: Adult; Aged; Aspirin; Asthma; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Indoles; Leu | 1999 |
Ulcerative colitis following introduction of zafirlukast and corticosteroid withdrawal in severe atopic asthma.
Topics: Aged; Asthma; Colitis, Ulcerative; Drug Therapy, Combination; Glucocorticoids; Humans; Hypersensitiv | 1999 |
Taking a look at new advances in asthma therapy.
Topics: Acetates; Anti-Asthmatic Agents; Asthma; Cyclopropanes; Humans; Indoles; Leukotriene Antagonists; Ne | 1999 |
Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal?
Topics: Acetates; Adrenal Cortex Hormones; Asthma; Chromones; Churg-Strauss Syndrome; Cyclopropanes; Eosinop | 1999 |
Leukotriene receptor antagonist drugs for asthma.
Topics: Acetates; Anti-Asthmatic Agents; Asthma; Chronic Disease; Cyclopropanes; Humans; Indoles; Leukotrien | 1999 |
Drugs for asthma.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adrenergic beta | 2000 |
The use of newer asthma and allergy medications during pregnancy. The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI).
Topics: Abnormalities, Drug-Induced; Acetates; Administration, Inhalation; Administration, Intranasal; Admin | 2000 |
Zafirlukast and cromolyn are effective first-line therapies for child asthma.
Topics: Anti-Asthmatic Agents; Asthma; Child; Cromolyn Sodium; Humans; Indoles; Phenylcarbamates; Sulfonamid | 2000 |
Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast.
Topics: Adult; Aged; Alleles; Anti-Asthmatic Agents; Asthma; Cysteine; Eosinophils; Female; Genotype; Glutat | 2000 |
Churg-Strauss syndrome: is there an association with leukotriene modifiers?
Topics: Acetates; Administration, Inhalation; Adrenal Cortex Hormones; Anti-Asthmatic Agents; Asthma; Churg- | 2000 |
Evaluation of the effects of zafirlukast 40 mg b.i.d. in addition to preexisting therapy of high-dose inhaled steroids on symptomatic patients with reversible respiratory obstruction: preliminary data.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Ag | 2000 |
One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Androstadienes; Anti-Inflammatory Agents; Asthma; Fem | 2001 |
Allergy and angiitis: two aspects of Churg-Strauss syndrome.
Topics: Anti-Asthmatic Agents; Asthma; Biopsy; Churg-Strauss Syndrome; Granuloma; Humans; Indoles; Leukotrie | 2001 |
Enhanced prostaglandin E2 secretion in sputum from asthmatic patients after zafirlukast therapy.
Topics: Adult; Aged; Anti-Asthmatic Agents; Asthma; Blood Proteins; Dinoprostone; Eosinophil Granule Protein | 2001 |
Use of changes in symptoms to predict changes in lung function in assessing the response to asthma therapy.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; | 2001 |
Safety of antileukotriene agents in asthma management.
Topics: Acetates; Asthma; Churg-Strauss Syndrome; Clinical Trials as Topic; Cyclopropanes; Humans; Hydroxyur | 2001 |
Asthma treatment with inhaled corticosteroids versus antileukotrienes: what exhaled nitric oxide studies do and do not tell us.
Topics: Administration, Inhalation; Androstadienes; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; | 2001 |
[The relationship between eosinophils, activated T lymphocyte, leukotreine and the exercise-induced asthma].
Topics: Adult; Anti-Asthmatic Agents; Asthma; Asthma, Exercise-Induced; Biomarkers; Blood Proteins; Eosinoph | 2001 |
Pharmacoeconomic studies of asthma controller drugs: marketing gimmick or icing on the cake?
Topics: Acetates; Administration, Inhalation; Administration, Oral; Androstadienes; Anti-Inflammatory Agents | 2002 |
Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population.
Topics: Acetates; Administration, Inhalation; Adolescent; Adult; Androstadienes; Anti-Asthmatic Agents; Anti | 2002 |
Inhaled fluticasone and zafirlukast in persistent asthma.
Topics: Androstadienes; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Fluticasone; Humans; Indole | 2002 |
[Zafirlukast in treatment of nasal polyps in patients with aspirin intolerant bronchial asthma--preliminary report].
Topics: Adult; Aspirin; Asthma; Drug Hypersensitivity; Humans; Indoles; Leukotriene Antagonists; Male; Nasal | 2002 |
Churg-Strauss syndrome in a case of asthma.
Topics: Adolescent; Anti-Bacterial Agents; Asthma; Churg-Strauss Syndrome; Female; Humans; Indoles; Leukotri | 2002 |
5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists.
Topics: Acetates; Adult; Arachidonate 5-Lipoxygenase; Asthma; Cyclopropanes; Forced Expiratory Volume; Genot | 2002 |
Inhibition of allergic bronchoconstriction in asthmatics by the leukotriene-antagonist ICI-204,219.
Topics: Adult; Allergens; Asthma; Bronchi; Bronchial Provocation Tests; Forced Expiratory Volume; Humans; Hy | 1991 |